FDA Approves Cefepime-Zidebactam Injection - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Cefepime-Zidebactam Injection

Phase 3 ENHANCE-1 results showed higher composite clinical cure and microbiologic response rates with cefepime-zidebactam vs meropenem in hospitalized adults with complicated urinary tract infection or acute pyelonephritis.

  • By

  • Kathryn Wighton

  • June 3, 2026

  • 2 min

Share

  • 1

    The FDA approved cefepime and zidebactam for treating complicated urinary tract infections in adults.

  • 2

    The approval is based on the phase 3 ENHANCE-1 trial, which involved 530 patients across multiple countries.

  • 3

    Cefepime and zidebactam achieved a composite clinical cure rate of 89%, compared to 68% for meropenem.

  • 4

    The treatment combines a fourth-generation cephalosporin with a non-beta-lactam antibacterial and beta-lactamase inhibitor.

  • 5

    Cefepime and zidebactam received Priority Review, Fast Track, and Qualified Infectious Disease Product designations from the FDA.

Original Source(s)

FDA Approves Cefepime-Zidebactam Injection

  • by Kathryn Wighton

  • June 3, 2026

Related Content

Knee sepsis may be rare across tibial fracture care

Investigators documented acute knee sepsis after both intra- and extra-articular nailing of open tibial shaft fractures.

PrEP surfing common among MSM

Reliance on partners’ PrEP use was more common among younger men and those who had used PrEP in the previous 6 months.

Plasma versus whole blood multiplex droplet digital PCR for pathogen detection in ICU patients with clinically suspected sepsis: a prospective multicenter cohort study